Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
about
Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experienceCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasRacial differences in the incidence of mesenchymal tumors associated with EWSR1 translocationPIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications.Trabectedin and its potential in the treatment of soft tissue sarcoma.Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7.Multifocal myxoid liposarcoma--metastasis or second primary tumor?: a molecular biological analysis.Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wallIdentification of a gene expression driven progression pathway in myxoid liposarcoma.Liposarcoma in children and young adults: a multi-institutional experience.Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma.PPARĪ³ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaMetachronous multifocal myxoid liposarcoma involving the gastrointestinal tract. Management and literature reviewLessons learned from the study of 10,000 patients with soft tissue sarcoma.Advances in the targeted therapy of liposarcoma.Assessment of fusion gene status in sarcomas using a custom made fusion gene microarray.Transcriptional profiling of mammary gland in Holstein cows with extremely different milk protein and fat percentage using RNA sequencingMolecular genetics of pediatric soft tissue tumors: clinical application.Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma.Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcomaClassification and subtype prediction of adult soft tissue sarcoma by functional genomics.Deregulation of dicer and mir-155 expression in liposarcoma.FDG-PET Lacks Sufficient Sensitivity to Detect Myxoid Liposarcoma Spinal Metastases Detected by MRI.Primary liposarcoma of liver: a rare case and literature reviewVariation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.Myxoid liposarcoma with negative features on bone scan and [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomographySurgery quality and tumor status impact on survival and local control of resectable liposarcomas of extremities or the trunk wall.A phase II trial with rosiglitazone in liposarcoma patients.Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.Fusion genes and their discovery using high throughput sequencing.A case of myxoid liposarcoma of the breastMyxoid liposarcoma with cartilaginous differentiation: a case study with cytogenetical analysisCancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Primary Retroperitoneal Myxoid LiposarcomasAxitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid LiposarcomaLiposarcoma: molecular genetics and therapeutics.Subcutaneous myxoid and round cell liposarcoma
P2860
Q21296661-50F00320-832E-4EC3-BC43-DC985FBFB564Q28076210-79FEDF96-A857-4E41-9B2A-37EAE06F3241Q28302617-F0F22309-0688-4497-8C18-352CB9552F39Q33273560-FDFD9FE0-1343-4D42-A251-79366583A63BQ33380903-ED0DAD5C-CE85-4FA1-B580-ED9EE8A8BF84Q33794219-A35EBFDC-4C03-4F37-973E-5DAB48E08932Q33856240-D306BB83-6F22-4BC9-804A-5A802B813637Q34026081-FC933681-6250-4C19-A90E-394D4DF227BDQ34164507-78FB1E16-71ED-4299-9B54-49341506643CQ34227540-7B570080-E68B-4FE9-80BE-37A4C306BA84Q34627494-FDDD4071-3122-4F13-B2B8-3D55BA7B92CCQ34634538-1EA1A10A-BB60-4611-BCBE-DAAB8A5A1BB2Q34635550-B7129FB0-CED8-49CF-B77E-72224CAF4A0DQ34660786-98609B77-C09B-4387-9159-D66A1F09B590Q34663883-D204CDE7-84AA-4CAE-80A2-68EA9F2C01D6Q34952133-7380F1E6-328B-4302-AD46-D40D9A39BD32Q34962577-47E0F466-369A-4381-A10B-DC600B3C60E0Q35127278-08192268-4A09-4C7B-91F7-C8720C725817Q35183100-08FD6FB6-1DC2-4A2F-AEE9-AD09425A3A1DQ35416886-2EB30AC4-CFEE-4771-A148-DD3A9014D1F9Q35586969-6672692D-8DB0-4F32-923C-5A2C48A1E189Q35700114-257152DC-678D-4351-861E-343E9272FE1CQ35791796-9E4A5E73-B552-4A97-AE5D-2E3984AF878AQ35833073-B9E22A40-D86F-4130-9DA7-1871DBC66141Q35869165-7F79F2F5-3751-4800-8A78-635DBC96EC37Q35976196-5C641570-DB20-4F38-8C14-5D409135B2F5Q35995158-6A26D1E3-2970-4D62-918D-F1E8B3A0FA3FQ36500821-81F2CDDA-1B17-496C-8EBB-3B4FD167996BQ36585882-22466A69-ADB0-4639-AC4B-777EDC3E2A30Q36671304-8A72B6E3-2AD5-4175-B3AE-9351A2A3DB86Q36878798-CBA7DDA8-7446-4EF8-A682-224FA27DCBFEQ36909126-F5041F78-EF78-45BA-8AAE-41B400044087Q36956252-F2371BE4-614C-4BBA-BA1F-FFFBEE024ACBQ36983451-2716E344-F72E-4F01-9089-3CE7C333107CQ37082518-B1D55649-F63E-4BAB-95A9-E1E8CE9CC1AEQ37136357-BEE42EFC-780E-4CD3-985D-C0197B41E052Q37268602-B8BEADAF-CBEF-4FF1-9343-F51C0D20782FQ37378403-05409AC1-93F8-45AE-BEF3-1E04C6998BF7Q37831160-C7F85C90-1D1D-4992-862F-55F50CD75FD9Q38263197-1E3DBEC3-7DF3-4F24-A145-5E144DA4C2F3
P2860
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
description
2001 nĆ® lÅ«n-bĆ»n
@nan
2001 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō“Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2001 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ¤Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2001幓ć®č«ę
@ja
2001幓č«ę
@yue
2001幓č«ę
@zh-hant
2001幓č«ę
@zh-hk
2001幓č«ę
@zh-mo
2001幓č«ę
@zh-tw
2001幓č®ŗę
@wuu
name
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@ast
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@en
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@nl
type
label
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@ast
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@en
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@nl
prefLabel
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@ast
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@en
Prognostic impact of P53 statu ...... opathologic study of 82 cases.
@nl
P2093
P1476
Prognostic impact of P53 statu ...... copathologic study of 82 cases
@en
P2093
Antonescu CR
Decuseara R
Goldblum JR
Tschernyavsky SJ
Woodruff JM
P304
P407
P577
2001-12-01T00:00:00Z